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OBJECTIVE — We investigated whether the antiproteinuric effect of the direct renin inhib-
itor aliskiren is comparable to that of irbesartan and the effect of the combination.
RESEARCHDESIGNANDMETHODS — Thiswasadouble-blind,randomized,cross-
over trial. After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and
albuminuria (100 mg/day) were randomly assigned to four 2-month treatment periods in
random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the
combination using identical doses. Patients received furosemide in a stable dose throughout the
study. The primary end point was a change in albuminuria. Secondary measures included
change in 24-h blood pressure and glomerular ﬁltration rate (GFR).
RESULTS — Placebo geometric mean albuminuria was 258 mg/day (range 84–2,361),
mean  SD 24-h blood pressure was 140/73  15/8 mmHg, and GFR was 89  27 ml/min per
1.73 m
2. Aliskiren treatment reduced albuminuria by 48% (95% CI 27–62) compared with
placebo (P  0.001), not signiﬁcantly different from the 58% (42–79) reduction with irbesartan
treatment (P  0.001 vs. placebo). Combination treatment reduced albuminuria by 71% (59–
79),morethaneithermonotherapy(P0.001andP0.028).Fractionalclearancesofalbumin
were signiﬁcantly reduced (46, 56, and 67% reduction vs. placebo). Twenty-four-hour blood
pressure was reduced 3/4 mmHg by aliskiren (NS/P  0.009), 12/5 mmHg by irbesartan (P 
0.001/P  0.002), and 10/6 mmHg by the combination (P  0.001/P  0.001). GFR was
signiﬁcantly reduced 4.6 (95% CI 0.3–8.8) ml/min per 1.73 m
2 by aliskiren, 8.0 (3.6–12.3)
ml/minper1.73m
2byirbesartan,and11.7(7.4–15.9)ml/minper1.73m
2bythecombination.
CONCLUSIONS — The combination of aliskiren and irbesartan is more antiproteinuric in
type 2 diabetic patients with albuminuria than monotherapy.
Diabetes Care 32:1873–1879, 2009
A
lbuminuriaisthebestavailablesur-
rogateparameterinthetreatmentof
diabetic nephropathy. Degree of
proteinuriaisassociatedwithriskofrenal
andcardiovascularevents(1).Proteinuria
reduction is associated with a slowing of
thedeclineinrenalfunction(2).Blockade
of the renin-angiotensin-aldosterone sys-
tem (RAAS) is the cornerstone treatment
of incipient and overt diabetic nephropa-
thy, and in type 2 diabetes angiotensin II
receptor blockers (ARBs) such as irbesar-
tan are considered standard treatment af-
ter the Irbesartan in Patients with Type 2
DiabetesandMicroalbuminuria(IRMA)2
Study (3) and Irbesartan Diabetic Ne-
phropathy Trial (IDNT) (1).
Aliskiren represents a new principle
ofblockingtheRAAS,inhibitingrenindi-
rectly and acting at the rate-limiting step.
The drug is approved for treatment of hy-
pertension but has also shown renopro-
tective potential in patients with type 2
diabetes and albuminuria (4,5).
Combining an ARB and a direct renin
inhibitor could offer improved RAAS
blockade by acting both at the receptor
level and at the ﬁrst step of the cascade.
We compared the antiproteinuric effect
of maximal recommended doses of
aliskiren,irbesartan,andthecombination
in patients with type 2 diabetes and albu-
minuria. We also assessed the impact of
the treatments on RAAS components and
biomarkers of inﬂammation, endothelial
dysfunction, and cardiovascular risk.
RESEARCH DESIGN AND
METHODS— This was a double-
blind, randomized, crossover trial in ac-
cordancewiththeDeclarationofHelsinki
and good clinical practice. The primary
objective was to assess albuminuria dur-
ing different treatments compared with
that with placebo; secondary objectives
were to assess effect on 24-h blood pres-
sure, glomerular ﬁltration rate (GFR),
biomarkers, and RAAS components. Pa-
tients were recruited from the Steno Dia-
betes Center, Gentofte, Denmark. The
protocol was approved by the local ethics
committee and the Danish Medicine
Agency. After informed consent, patients
attended a screening visit comprising lab-
oratory tests and evaluations of inclusion/
exclusion criteria. A 1-month washout
followed, in which all antihypertensive
treatment was stopped. Slow-release fu-
rosemide in a ﬁxed dose (mean dose 109
mg/24 h, range 60–360 mg/24 h) was
prescribed to prevent blood pressure
elevation and ﬂuid retention. Patients
used an electronic blood pressure device
(UA-779; A&D Instruments, Abingdon,
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Steno Diabetes Center, Gentofte, Denmark; the
2Department of Medicine, University Hospital,
Maastricht, the Netherlands; the
3Section of Vascular Pharmacology and Metabolism, Department of
InternalMedicine,ErasmusMC,Rotterdam,theNetherlands;the
4DepartmentofClinicalPhysiologyand
Nuclear Medicine, Glostrup Hospital, Denmark; the
5Department of Medical Endocrinology, University
Hospital of Copenhagen, Denmark; and the
6Faculty of Health Science, Aarhus University, Aarhus,
Denmark.
Corresponding author: Frederik Persson, frip@steno.dk.
Received 29 January 2009 and accepted 23 June 2009.
Published ahead of print at http://care.diabetesjournals.org on 8 July 2009. DOI: 10.2337/dc09-0168.
Clinical trial reg. no. NCT00464880, clinicaltrials.gov.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Emerging Treatments and Technologies
ORIGINAL ARTICLE
care.diabetesjournals.org DIABETES CARE, VOLUME 32, NUMBER 10, OCTOBER 2009 1873U.K.) to measure home blood pressure
throughout the study. Home blood pres-
sure exceeding 170/105 mmHg led to
exclusion.
Fromalistofprescreenedcandidates,
41 patients were screened for study par-
ticipation (supplementary Fig. 1, avail-
able in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc09-
0168/DC1). Nine of these were screen
failures mainly due to albuminuria levels
below the randomization requirement.
Thirty-two patients were randomly as-
signed, and 22 patients completed the
study. Of the 10 randomly assigned pa-
tients who left the study before comple-
tion,2died,1waslosttofollow-up,4had
an adverse event that led to exclusion (di-
arrhea, severe hypertension, recurrent
urinary tract infection, and dizziness),
and 3 withdrew consent. Twenty-six pa-
tients had the primary end point, albu-
minuria assessed after randomization,
and were included in the ﬁnal analysis;
the remaining six patients dropped out
shortly after random assignment and
were not included in the ﬁnal analysis.
After washout, patients attended a ran-
domization visit before 2 months of treat-
mentwithplacebo,300mgaliskirenonce
daily, 300 mg irbesartan daily, or the
combinationofthetwo,inrandomorder.
Patients with type 2 diabetes (World
HealthOrganizationcriteria)aged30–80
years were eligible for randomization
with baseline urinary albumin excretion
rate (UAER)  100 mg/24 h, hyperten-
sion (baseline ofﬁce blood pressure
135/85mmHg),andbaselineGFR40
ml/minper1.73m
2.Exclusioncriteriain-
cluded major cardiovascular disease
(within 6 months), heart failure (New
York Heart Association class II–IV), A1C
11%, and history of malignancy.
Cardiovascular history was assessed at
screening using medical records and an
electrocardiogram. Seven patients had
previously been exposed to aliskiren.
There was no washout of study med-
ication between the treatment periods.
Rather, we used active washout: during
the ﬁrst 14 days of all treatments, every
patient received 150 mg aliskiren daily to
avoid risk of hypotension or a drastic in-
crease in blood pressure in the switch
fromplacebotocombinationtreatmentor
vice versa.
During the last 3 days of each treat-
ment,patientscollectedthreeconsecutive
24-hurinesamplesforassessmentofgeo-
metricmeanUAER.Atthelastdayofeach
treatment period, patients attended our
clinic for assessment of GFR and mount-
ing of standard Takeda 24-h blood pres-
sure devices (TM2421, version 7; A&D
Medical, Tokyo, Japan). Measurements
were performed every 15 min from 7 to
23 h (daytime) and every 30 min from 23
to 7 h (nighttime). Nondipping was de-
ﬁned as 10% difference between day-
time and nighttime blood pressure. GFR
was measured as plasma clearance of
51Cr-EDTA (6).
Urinaryalbuminandcreatininecon-
centrations were determined on a turbi-
dimetric Hitachi 912 system (Roche
Diagnostics, Mannheim, Germany). Sam-
ples for prorenin, plasma renin activity
(PRA),high-sensitivityPRA(hs-PRA),im-
munoreactiveplasmareninconcentration
(ir-PRC), angiotensinogen, ANG I, ACE
activity, ANG II, and aldosterone levels
were determined after 30 min of supine
rest, and the plasma was frozen after cen-
trifugation (80°C).
RAAS components and biomarkers
were measured at baseline and at the end
of treatment periods. Biomarkers of in-
ﬂammation, endothelial dysfunction, and
cardiovascular risk were measured: high-
sensitivity C-reactive protein (hs-CRP)
(enzyme immunosorbent assay [EIA];
Dako, Glostrup, Denmark); serum solu-
ble vascular adhesion molecule-1 and
serum soluble intercellular adhesion
molecule-1 (EIA; Diaclone, Besanc ¸on,
France); plasma plasminogen activator
inhibitor-1 (HYPHEN BioMed kit; An-
dresy, France); serum NH2-terminal-
probrain natriuretic peptide (EIA kit;
Biomedica, Wien, Austria); ﬁbrinogen
(immunoturbidimetry); and plasma
asymmetrical dimethyl arginine (high-
performance liquid chromatography).
Total renin concentration, prorenin con-
centration,plasmaangiotensinogen,PRA,
and biomarkers of inﬂammation and en-
dothelial dysfunction were measured us-
ing methodology described previously
(4). ir-PRC was measured with an im-
munoradiometric kit (Renin III; CisBio,
Gif-sur-Yvette, France). hs-PRA was
measuredbyin-houseradioimmunoassay
of ANG I formed during incubation of 25
l plasma and 50 pmol sheep angio-
tensinogen for3ha t37°C in a total reac-
tion volume of 100 l. The assay was
double calibrated against ANG I and the
international reference preparation of re-
nin, 68/356, from NIBSC (Hertfordshire,
U.K.). Plasma ANG I and ANG II were
measured using in-house radioimmuno-
assays and ethanol extraction of plasma
samples. Antibodies were raised in rab-
bits, and calibrators were purchased from
NIBSC. ACE activity was determined us-
ing a commercial radioenzymatic assay
(ACE direct; Bu ¨hlmann-Laboratories,
Scho ¨nenbuch, Switzerland).
Randomization was blinded to all in-
vestigators, and the study drugs were
packed and labeled before delivery to the
site. The treatment code was revealed
only after database lock.
Statistical analysis
It was estimated that 20 patients com-
pleting the study could provide 80%
power to demonstrate a signiﬁcant differ-
ence between two treatments in antipro-
teinuric effect (UAER) if the true
difference was 15%. This was based on
the assumption that intrasubject coefﬁ-
cient of variation for the UAER was 13%.
Figure1—ChangeinUAER(percentage)versusplaceboduringtreatmentwith300mgaliskiren
daily, 300 mg irbesartan daily, or the combination (P  0.001 vs. placebo for all treatments).
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analyzed by a PROC MIXED model with
sequence, treatment, and period as ﬁxed
factors and subject (nested in sequence)
as a random factor. For 24-h blood pres-
sure data, daytime average, nighttime av-
erage,and24-haveragevaluesforsystolic
blood pressure and diastolic blood pres-
sure were analyzed using a PROC MIXED
model with sequence, treatment, and pe-
riodasﬁxedfactorsandsubject(nestedin
sequence) as a random factor. Extra anal-
yses were performed to test the assump-
tion of no carryover effect by ﬁtting a
carryover effect term into the model. GFR
results and all other laboratory assess-
ment data were analyzed similarly to
blood pressure data. A two-sided P
value  0.05 was considered signiﬁcant.
The correlation between changes in
albuminuria and changes in hs-PRA or
ANG II were assessed by a nonparametric
Spearman correlation coefﬁcient. Corre-
lations between changes in albuminuria
and changes in ir-PRC were assessed by
linear regression analysis within each ac-
tive treatment (aliskiren, irbesartan, and
aliskiren/irbesartan combination) and for
allactivetreatmentscombined.Fractional
clearancewascalculatedusingurinesam-
ples collected during GFR measurements
(urinary albumin excretion/serum albu-
min concentration  GFR), and log-
transformedlevelswerecomparedusinga
paired t test. Statistical analyses were per-
formed using SAS (version 8.2 or higher;
SAS Institute, Cary, NC) and SPSS (ver-
sion 14.0; SPSS, Chicago, IL).
RESULTS— Baseline demographic
data are shown in Table 1. Primary and
secondary objectives were met. During
placebo treatment geometric mean UAER
was 258 (range 84–2,361) mg/day,
meanSD24-hbloodpressurewas140/
73  15/8 mmHg, daytime blood pres-
sure was 144/76  17/9, and nighttime
blood pressure was 130/68  17/9.
Eleven patients were deﬁned as nondip-
pers. GFR was 89  27 ml/min per 1.73
m
2 and mean serum creatinine was 88
mol/l.
Aliskiren treatment led to a signiﬁ-
cant reduction in albuminuria by 48%
(95% CI 27–62) compared with placebo
(P0.001)butnotsigniﬁcantlydifferent
from irbesartan, lowering UAER by 58%
(42–70) (P  0.001 vs. placebo). Combi-
nation treatment reduced albuminuria by
71%(59–79)(P0.001)comparedwith
placebo, signiﬁcantly more than with ei-
ther monotherapy (P  0.001 and P 
0.028). The relative difference between
aliskiren and combination treatment was
31%. To adjust for treatment-induced
changes in GFR and the potential inﬂu-
enceonalbuminuriareduction,wecalcu-
lated fractional clearance, which was
reduced by 46% versus placebo during
aliskiren treatment (P  0.021), by 56%
versus placebo during irbesartan treat-
ment (P  0.002), and by 67% versus
placebo during combination treatment
(P0.001).Therewerenoindicationsof
carryover effects on the results.
Systolic/diastolic24-hbloodpressure
was reduced 3/4 mmHg by aliskiren (NS/
P  0.009), 12/5 mmHg by irbesartan
(P  0.001/P  0.002), and 10/6 mmHg
by the combination (P  0.001/P 
0.001) versus placebo. There was no sig-
niﬁcant change in 24-h blood pressure
from irbesartan to combination therapy.
A correlation was found between
change in albuminuria and change in
24-h diastolic blood pressure during all
treatments (P  0.039). Seated ofﬁce
systolic/diastolic blood pressure was re-
duced 7/4 mmHg by aliskiren, 6/4
mmHg by irbesartan, and 12/8 mmHg
by the combination, all statistically sig-
niﬁcant compared with placebo, except
fordiastolicbloodpressureduringirbe-
sartan treatment.
GFR was signiﬁcantly reduced 4.6
(95%CI8.8–0.3)ml/minper1.73m
2by
aliskiren (P  0.037), 8.0 (12.3–3.6) ml/
min per 1.73 m
2 by irbesartan (P 
0.001), and 11.7 (15.9–7.4) ml/min per
1.73 m
2 by the combination (P  0.001)
compared with placebo. Aliskiren signif-
icantlyreducedhs-PRA,ANGI,andANG
II by 87, 75, and 52%, respectively, com-
pared with placebo; irbesartan had the
opposite effect (Table 2). When com-
bined, the activating effect of irbesartan
was counteracted by aliskiren, reducing
hs-PRA, ANG I, and ANG II by 88, 78,
and 56%, respectively, compared with
irbesartanmonotherapy.Whereascombi-
nation treatment caused a 1,068% in-
crease in ir-PRC versus a 279% increase
during aliskiren monotherapy and a
178% increase during irbesartan mono-
therapy, hs-PRA was reduced 47% com-
pared with placebo after combination
therapy.PRAmeasuredbyaconventional
method was affected similarly to hs-
PRA, although the changes were smaller
(Table 2). The renin-speciﬁc activity
(renin bioactivity/total renin mass) was
3 and 4% after aliskiren and combina-
tion therapy compared with placebo,
respectively, thereby conﬁrming that
96–97% of renin was aliskiren bound.
During irbesartan monotherapy, renin-
speciﬁc activity increased 52% com-
pared with placebo.
Asigniﬁcantcorrelationbetweenre-
duction in albuminuria and increase in
ir-PRC was observed for all active treat-
ments combined (r
2  0.597, P 
Table 1—Demographics of the 32 randomly assigned patients with type 2 diabetes, hyperten-
sion, and albuminuria and the 26 included in the ﬁnal analysis
Total randomized
population
Included in
analysis
n 32 26
Age (years) 60.3  9.0 59.8  9.2
Male (%) 25 (78) 20 (77)
Caucasian (%) 32 (100) 26 (100)
Height (cm) 175  9 175  10
Weight (kg) 99.9  20.6 100.9  21.4
BMI (kg/m
2) 32.3  5.4 32.7  5.5
A1C (%) 8.1  1.3 8.2  1.3
Total cholesterol (mmol/l) 3.7  0.8 3.8  0.8
Smoking 10 8
CVD history 4 1
Blood pressure medications before study
inclusion (n) 2.5  0.8 2.3  0.8
RAAS blocking treatment prior to study
inclusion (n)3 0 2 4
Baseline 24-h blood pressure (mmHg)* 142/74  12/8 141/74  12/7
Baseline UAER (mg/day)* 307 (87–1,378) 275 (103–1,088)
Data are means SD, n, or mean (range). *Baseline was deﬁned as day of randomization. Values from the
placebo treatment period were used in end point analysis.
Persson and Associates
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lation between changes in albuminuria
and increase in ANG II during irbesar-
tan treatment (correlation coefﬁcient
0.486, P  0.022); no signiﬁcant cor-
relationswereobservedintheothertreat-
ment groups.
Table 2 depicts changes in cardiovas-
cular biomarkers compared with placebo
levels. hs-CRP was reduced 35%from the
placebo level with aliskiren (P  0.047)
and 35% with irbesartan (P  0.043).
Other statistically signiﬁcant changes
from placebo levels were a 6% reduction
in soluble intracellular adhesion mole-
cule-1 (P  0.017) observed with the
combination treatment and a 7% reduc-
tion in ﬁbrinogen during aliskiren treat-
ment (P  0.037). No treatment led to
signiﬁcant changes from placebo levels in
any of the other cardiovascular biomark-
ers (Table 2).
The most frequent adverse events
wereurinarytractinfection(fourpatients,
one male), pneumonia (three patients),
and cough (three patients), occurring
during different treatments. Anemia and
hypomagnesemia were detected in two
patients during the combination treat-
ment. Compared with each mono-
therapy, combination treatment showed
an increase in plasma potassium by 0.2
mmol/l (P  0.036). No patients devel-
oped hyperkalemia (deﬁned as plasma
potassium 5.5 mmol/l). There were no
incidences of hypotension. One patient
dropped out during the placebo period
after several systolic blood pressure read-
ings 180 mmHg.
Two patients died before the ﬁrst
measurement of albuminuria after the
randomization and were not included in
the ﬁnal end point analysis. The ﬁrst
deathwasthatofa42-year-oldobeseman
(BMI42kg/m
2)withahistoryofischemic
heart disease, myocardial infarction, and
hypertension 4 years before study entry.
The patient experienced sudden cardiac
arrest, seemingly after a myocardial in-
farction during aliskiren treatment. The
second death was that of a hypertensive,
obese, 73-year-old man with diabetes du-
ration of 16 years. Sudden death was pos-
sibly caused by a pulmonary embolism
during the placebo period. The deaths
were instantly reported to relevant au-
thorities and were not suspected as being
related to any of the drugs studied. Sub-
sequently,homebloodpressuremeasure-
ment frequency was increased from twice
weekly to twice daily, and patients were
instructed to contact the investigator by
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if any measurement was 160/100
mmHg. Extra measurements of sodium,
potassium, and creatinine were intro-
duced 3 weeks into each treatment
period.
CONCLUSIONS — In this explor-
atory study, we demonstrated that treat-
ment with 300 mg aliskiren once daily
was as efﬁcient in reducing albuminuria
as standard therapy with 300 mg irbesar-
tan once daily. When we combined the
two treatments at the same doses, the re-
duction in albuminuria was enhanced.
The added antiproteinuric effect with
combination treatment compared with
aliskiren alone was 31%.
Giventhatthereductionsin24-hsys-
tolic blood pressure with aliskiren were
unexpectedly small compared with those
with placebo relative to 24-h diastolic
blood pressure changes and were sub-
stantially lower than the ofﬁce systolic
blood pressure measurements in this
study,weconductedathoroughreviewof
potential ﬂaws in data collection, storage,
devicecalibration,reporting,andcalcula-
tion. There was no evidence to indicate
that the ambulatory data collection, stor-
age, or reporting was ﬂawed, and the
unexpected results could be a chance
occurrence.
Our study suggested that the com-
bination of aliskiren and irbesartan
had an additional RAAS blocking effect
compared with monotherapy because
a synergistic increase in ir-PRC was ob-
served with the combination, which
was related to the antiproteinuric effect,
whereas hs-PRA was reduced 50%
compared with the reduction with
placebo.
As opposed to the Aliskiren in the
Evaluation of Proteinuria in Diabetes
(AVOID) study (5), which showed an ad-
ditional 20% albuminuria reduction after
24weeksoftreatmentwithaliskirencom-
pared with placebo added to the maximal
recommended dose of losartan and opti-
mal antihypertensive therapy, this is the
ﬁrst study with a head-to-head compari-
son between aliskiren and irbesartan
treatment. No other antihypertensive
drugsexceptforfurosemidewereallowed
in our study, thereby offering a clearer
picture of the effect of the two com-
pounds used, compared with the AVOID
study, in which aliskiren was combined
with losartan and a mixture of other anti-
hypertensivedrugs.Thisstudyisdifferent
with regard to patient population, with a
lower mean baseline UAER compared
with that in the AVOID study. In addi-
tion, we assessed the effect of renin inhi-
bition on GFR, a measurement that is
moreprecisethantheestimatedGFRused
in the AVOID study.
RAAS blockade is believed to reduce
proteinuria through several different
mechanisms: the mean transcapillary hy-
draulic pressure difference, the glomeru-
lar surface area, and the size and charge
selectivity of the glomerular ﬁlter. In dia-
betic nephropathy several of these vari-
ables are abnormal, and RAAS blockade
has been demonstrated to normalize di-
rectly measured or estimated glomerular
hydraulic pressure (7–9), to reduce the
shunt-like defects in the membrane, at
least in part (10), and to restore the
charge-selectivity properties of the glo-
merular membrane (11).
Aliskiren is thought to reduce albu-
minuria by the same mechanism as dur-
ing treatment with ACE inhibitors or
ARBs. Recently, Fisher et al. (12) have
shown that aliskiren treatment increases
renal plasma ﬂow to a larger extent than
the ACE inhibitor captopril. The increase
in renal plasma ﬂow may be a response to
angiotensin AT1 receptor–dependent re-
duction of the vascular tone in the efferent
arteriole.Reducedvasculartoneintheeffer-
ent glomerular arteriole could be responsi-
ble for the decrease in intraglomerular
pressure,leadingtothereductioninalbu-
minuria and GFR as demonstrated in our
study. Combination treatment may re-
ducevasculartonetoagreaterextentthan
monotherapy. More research on the im-
pact of renin inhibition on renal physiol-
ogy is needed.
GFR changes seemed to be depen-
dent on treatment during the study. Al-
though the combination reduced GFR
up to 12 ml/min (95% CI 15.9–7.4), we
interpreted this as an reversible hemo-
dynamic change and not as an indica-
tion of nephrotoxicity (13). In fact, it
has been shown that an early hemody-
namic reduction in GFR can translate
into long-term renoprotection (13).
When the albuminuria reduction was
adjusted during combination treatment
for changes in GFR (fractional clear-
ance), it was 11% higher than during
irbesartan treatment, a nonsigniﬁcant
change that was possibly due to a small
sample number.
Signs of more effective RAAS block-
ade were evident from the synergistic
effect of combination treatment on ir-
PRC. This conclusion is based on the
fact that renin release into plasma is
proportional to the interruption of the
permanent negative feedback loop of
ANG II on renin secretion (14). Com-
bining aliskiren with irbesartan pro-
vided a 12-fold increase in ir-PRC, but
still with a 50% reduction in hs-PRA
compared with changes during the pla-
cebo period. This renin rise could re-
ﬂect a high degree of intrarenal RAAS
blockadeduringcombinationtreatment
as compared with that for the mono-
therapies, as has been suggested in non-
diabetic patients (15). The reductions
in albuminuria in our study were corre-
latedwiththeriseinir-PRC,supporting
the concept of increased intrarenal
RAAS blockade underlying the addi-
tional effects observed during combina-
tion treatment. Compared with other
studies of dual RAAS blockade, the rise
in ir-PRC is higher in dual RAAS block-
ade using aliskiren than in dual RAAS
blockade with an ACE inhibitor and an
ARB (5,16,17). Such marked increases
in renin during aliskiren treatment have
been noted before (18). Apart from re-
ﬂecting more complete (intrarenal) RAAS
blockade, they may also be due to the de-
tection of prorenin as renin (19) or a
change in the renin half-life after its bind-
ing to aliskiren (20).
PRA was measured both by a conven-
tional method and by a new high-
sensitivity assay (hs-PRA), which is
independent of endogenous substrate
variation (21). Because high PRA levels
confer the risk of cardiovascular disease
(22), it will be interesting to evaluate
long-term effects of direct renin inhibi-
tion in the ongoing Aliskiren Trial in
Type 2 Diabetes Using Cardio-Renal
Endpoints (ALTITUDE), providing data
on hard cardiovascular and renal end
points (23).
The antihypertensive effect of aliskiren
was smaller than that found in previous
larger studies (16), although the ofﬁce
blood pressure reduction did not differ
from that caused by irbesartan. More re-
search on the possible differential dosing of
aliskiren treatment is warranted.
The Ongoing Telmisartan Alone and
in Combination with Ramipril Global
Endpoint Trial (ONTARGET) investiga-
tors(24)concludedthatinacardiovascu-
lar risk population, dual RAAS blockade
with the ARB telmisartan and the ACE in-
hibitor ramipril is equivalent in reducing
cardiovascular events compared with ei-
therasmonotherapy,althoughwithmore
frequent adverse events, including renal
Persson and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 32, NUMBER 10, OCTOBER 2009 1877adverse events. Almost 3,000 of the par-
ticipating25,260patientshadmicroalbu-
minuria at baseline, and substudies of
albuminuria effects are expected. Sev-
eral short-term studies using dual RAAS
blockade in diabetic nephropathy have
shown promising antiproteinuric ef-
fects, as reviewed by Rossing (17), but
the largest study so far (25) did not
show additional beneﬁts of a combina-
tionoframiprilandirbesartan,compared
with ramipril monotherapy, in terms of
albuminuria reduction after 20 weeks.
The only biomarker showing a sys-
tematic reduction during treatment was
hs-CRP.
The sample size and the short treat-
ment periods are obvious limitations of
the study. The size was, however, sufﬁ-
cient to demonstrate the likely beneﬁcial
effect of combination therapy with
aliskiren and irbesartan, although we
evaluated a surrogate end point. In addi-
tion, the discrepancy between 24 h and
ofﬁce blood pressure readings compli-
cates interpretation of the results. Studies
evaluating mortality and morbidity are
ongoingandwillprovidefurtherinforma-
tion on dual RAAS blockade with
aliskiren.
In summary, we demonstrate an anti-
proteinuric effect of dual RAAS blockade
with aliskiren and irbesartan in combina-
tion compared with either treatment
alone in patients with type 2 diabetes, hy-
pertension, and albuminuria. The syner-
gistic effect on ir-PRC illustrates a higher
degree of intrarenal RAAS blockade dur-
ing combination treatment.
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